Seminars in Nuclear Medicine
Volume 31, Issue 4 , Pages 342-349 , October 2001

The impact of recent advances in immunology and cancer therapy on nuclear medicine

  • John G. McAfee

      Affiliations

    • Corresponding Author InformationAddress reprint requests to John G. McAfee, MD, Department of Nuclear Medicine, Clinical Center, The National Institutes of Health, Bldg 10, Room 1C401, 9000 Rockville Pike, Bethesda, MD 20892-1180.
    • ,
  • Thomas J. MacVittie

References 

  1. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. J Exp Med. 1973;137:1142–1162
  2. Reid CDL. The biology and clinical applications of dendritic cells. Transfusion Med. 1998;8:77–86
  3. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and down-regulated by tumor necrosis factor. J Exp Med. 1994;179:1109–1118
  4. Lotze MT. Getting to the source: Dendritic cells as therapeutic reagents for the treatment of patients with cancer. Ann Surg. 1997;226:1–5
  5. Lotze MT, Thomson AW. In: Dendritic Cells: Biology and Clinical Applications. New York, NY: Academic Press; 1999;
  6. Jonuleit H, Knop J, Enk AH. Cytokines and their effects on maturation, differentiation and migration of dendritic cells: Review. Arch Dermatol Res. 1996;289:1–8
  7. Rescigno M, Granucci F, Ricciardi-Castagnoli P. Dendritic cells at the end of the millennium. Immunol Cell Biol. 1999;77:404–410
  8. Dieu-Nosjean M-C, Vicari A, Lebecque S, et al. Regulation of dendritic cell trafficking: A process that involves the participation of selective cytokines. J Leukocyte Biol. 1999;66:252–262
  9. Stumbles PA. Regulation of T helper cell differentiation by respiratory tract dendritic cells. Immunol Cell Biol. 1999;77:428–433
  10. MacPherson GG, Liu LM. Dendritic cells and Langerhans cells in the uptake of mucosal antigens. Curr Top Microbiol Immunol. 1999;236:33–53
  11. Bassano DA, McAfee JG. Cellular radiation doses of labeled neutrophils and platelets. J Nucl Med. 1979;20:255–259
  12. Lambert C, Mease RC, Avren L, et al. Radioiodinated (aminostyryl)pyridinium (ASP) dyes: New cell membrane probes for labeling mixed leukocytes and lymphocytes for diagnostic imaging. Nucl Med & Biol. 1996;23:417–427
  13. Albright JW, Mease RC, Lambert C, et al. Effects of aging on the dynamics of lymphocyte organ distribution in mice: Use of a radioiodinated cell membrane probe. Mech Ageing Dev. 1998;101:197–211
  14. Austyn JM, Kupiec-Weglinski JW, Hankins DF, et al. Migration patterns of dendritic cells in the mouse. J Exp Med. 1988;167:646–651
  15. Austyn JM. Dendritic cells. Curr Opin Hematol. 1998;5:3–15
  16. Barratt-Boyes SM, Watkins SC, Finn OJ. In vivo migration of dendritic cells differentiated in vitro: A chimpanzee model. J Immunol. 1997;158:4543–4547
  17. Morse MA, Coleman RE, Akabani G. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res. 1999;59:56–58
  18. Thomas R, Chambers M, Boytar R, et al. Immature human monocyte-derived dendritic cells migrate rapidly to draining lymph nodes after intradermal injection for melanoma immunotherapy. Melanoma Res. 1999;9:474–481
  19. Reid SD, Penna G, Adorini L. The control of T cell responses by dendritic subsets. Curr Opin Immunol. 2000;12:114–121
  20. Lissoni P, Vigore L, Ferranti R, et al. Circulating dendritic cells in early and advanced cancer patients: Diminished percent in the metastatic disease. J Biol Regul Homeost Agents. 1999;13:216–219
  21. Kochman S, Bernard J. Antitumor immune response and cancer vaccination: The critical role of dendritic cells. Curr Med Res Opin. 1999;15:321–326
  22. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med. 1998;4:328–332
  23. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. 1996;2:52–58
  24. Coventry BJ. CD1a positive putative tumor infiltrating dendritic cells in human breast cancer: Review. Anticancer Res. 1999;19:3183–3188
  25. Salgaller ML, Lodge PA, McLean JG, et al. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate. 1998;35:144–151
  26. Colaco CA. Why are dendritic cells central to cancer immunotherapy?. Mol Med Today. 1999;5:14–17
  27. Colaco CA. DC-based cancer immunotherapy: The sequel. Immunol Today. 1999;20:197–198
  28. Roake JA, Austyn JM. The role of dendritic cells and T cell activation in allograft rejection. Exp Nephrol. 1993;1:90–101
  29. Larsen CP. The role of graft-derived dendritic leukocytes in the rejection of vascularized organ allografts. Ann Surg. 1990;212:308–315
  30. Thomas R. Antigen presenting cells in rheumatoid arthritis. Springer Semin Immunopathol. 1998;20:53–72
  31. Pettit AR, Thomas R. Dendritic cells: The driving force behind autoimmunity in rheumatoid arthritis?. Immunol Cell Biol. 1999;77:420–427
  32. Masten BJ, Lipscomb MF. Dendritic cells: Pulmonary immune regulation and asthma. Monaldi Arch Chest Dis. 2000;55:225–230
  33. Bertorelli G, Bocchino V, Zhou X, et al. Dendritic cell number is related to IL-4 expresion in the airways of atopic asthmatic subjects. Allergy. 2000;55:449–454
  34. Van den Heuvel MM, van Beek NM, Brough-Holub E, et al. Glucocorticoids modulate the development of dendritic cells from blood precursors. Clin Exp Immunol. 1999;115:577–583
  35. Bochino V, Bertorelli G, Zhou X, et al. Short-term treatment with a low dose of inhaled fluticasone proprionate decreases the number of CD1a+ dendritic cells in asthmatic airways. Pulm Pharmacol Ther. 1997;10:253–259
  36. Hoogsteden HC, Verhoeven GT, Lambrecht BN, et al. Airway inflammation in asthma and chronic obstructive pulmonary disease with special emphasis on the antigen-preventing dendritic cells. Clin Exp Allergy. 1999;2:116–124
  37. Quesenberry PJ. Letter from the Editor-in-Chief. Growth Factor Frenzy. Exp Haematol. 1993;21:835–836
  38. 89P McAfee JG, Carrasquillo JA, Camera A, et al. Changes in skeletal images induced by granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with locally advanced and metastatic breast cancer. J Nucl Med. 1994;35:
  39. Hovgaard D, Schifter S, Rabol S, et al. In vivo kinetics of 111-Indium-labelled autologous granulocytes following i.v. administration of granulocyte-macrophage colony-stimulating factor. Eur J Haematol. 1992;48:202–207
  40. 235P McAfee JG, Carrasquillo JA, Falen SW, et al. Changes in skeletal images induced by granulocyte colony-stimulating factor. J Nucl Med. 1995;36:
  41. (letter) Maffioli LS, Castellani MR, Bombardieri E, et al. Changing biodistribution of gallium during G-CSF treatment in non-Hodgkin's diseases. Eur J Nucl Med. 1999;26:68–69
  42. Abdel-Dayem HM, Sanchez J, Al-Mohannadi S, et al. Diffuse thallium-201 uptake in hypermetabolic bone marrow following treatment with granulocyte stimulating factor. J Nucl Med. 1999;33:2014–2016
  43. 174P Keast RK, McAfee JG. Changes in Tc-99m-Nanocoll marrow localization as a result of treatment with recombinant human granulocyte colony stimulating factor in the canine model. J Nucl Med. 1993;34:
  44. Berlangieri SV, Peters WP, Coleman RE. Distribution of Tc-99m sulfur colloid during granulocyte colony-stimulating factor administration in autologous bone marrow transplantation. J Nucl Med. 1991;32:1013
  45. Burgeois P, Gassavelis C, Malarme M, et al. Bone marrow scintigraphy in breast cancer. Nucl Med Commun. 1989;10:389–400
  46. Yao WJ, Hoh CK, Hawkins RA, et al. Quantitative PET imaging of bone marrow glucose metabolic response to hematopoietic cytokines. J Nucl Med. 1995;36:794–799
  47. Abdel-Dayem HM, Rosen G, El-Zeftawy H, et al. Fluorine-18 fluorodeoxyglucose splenic uptake from extramedullary hematopoiesis after granulocyte colony-stimulating factor stimulation. Clin Nucl Med. 1999;24:319–322
  48. Sugawara Y, Zasadry KR, Kison PV, et al. Splenic fluorodeoxyglucose uptake increased by granulocyte colony-stimulating factor therapy: PET imaging results. J Nucl Med. 1998;23:93–98
  49. Hollinger EF, Alibazog H, Ali A. Hematopoietic cytokine-mediated FDG uptake simulates the appearance of diffuse metastatic disease on whole-body PET images. Clin Nucl Med. 1998;23:93–98
  50. Meyer MA, Nathan CA. Reduced F-18 fluorodeoxyglucose uptake within marrow after external beam radiation. Clin Nucl Med. 2000;25:279–280

PII: S0001-2998(01)80013-1

doi: 10.1053/snuc.2001.26198

Seminars in Nuclear Medicine
Volume 31, Issue 4 , Pages 342-349 , October 2001

Article Tools